P7 Cancer – P7Medicine S.E.A.

P7 CANCER

Years of Experience, Latest Science, and Innovative Technologies for Personalized Cancer Therapy

ONCOASSAY®
Personalized Cancer Diagnosis

ONCOTHERA
Personalized Cancer Therapy

HEALI
Personalized Cancer Management Program

LIFE UP
VIP Personalized Treatment

P7Cancer

The Importance of
Personalized Cancer Therapy

Cancer is one of the most significant health challenges today and the second leading cause of death worldwide. According to the WHO, 9.6 million people died from cancer in 2018, with this number expected to rise to over 13 million by 2030.

Recent clinical studies have shown that personalized medicine approaches yield significantly better outcomes compared to conventional treatment strategies for cancer patients.

Despite tumor resection, many patients experience recurrence or metastatic conditions. Research indicates that genetic background, along with lifestyle and environmental factors, plays a crucial role in cancer development. Additionally, therapeutic responses vary among patients with the same type of cancer treated with identical regimens. These findings underscore the importance of considering genetic and molecular factors in cancer treatment.

Personalized cancer therapy, which takes these factors into account, offers a more effective approach to combating this disease.

P7Cancer combines the cutting-edge technologies and methodologies of ONCOASSAY®, ONCOTHERA, HELAI, LIFE UP to provide a comprehensive approach to diagnosing and treating cancer diseases.

ONCOASSAY®

ONCOASSAY® is one of our innovated precise personalized medicine approaches, especially designed for the prediction and treatment suggestions of cancer in people with familial history and/or creating individual-based strategy for cancer patients in different stages.

Using the most advanced molecular and cellular technologies, ONCOASSAY® investigates the individual tumor as a heterogeneous histologic and genetic tissue, based on patient’s tumor biology. To find the most functional types of mutations, complete transcriptional and translational analyses are conducted. There will be a team of oncologists, geneticists, and molecular biologists by patient’s side in order to define the best treatment strategy.

As an important feature of ONCOASSAY®, patient’s conventional clinical data is converted to digital format and combined with all the molecular bioinformatic data, leading to a rich and concentrated electronic health file for each patient. Based on diagnostic phase, ONCOASSAY® is divided into 4 different services of ONCOASSAY® A, B, C, and M, each could have Basic, Advanced, and Premium versions according to the required extent of analysis.

BENEFITS OF ONCOASSAY®

Enhanced treatment effectiveness (including survival outcomes),
Improved quality of life,
Reduced side effects,
Accessibility,
Precise prediction of recurrence,
Prediction and diagnosis of cancer formation at early stage.

TYPES OF ONCOASSAY®

ONCOASSAY® A

In Pre-Cancerous Phase

Method: Using modern and accurate genetic sequencing technology (NGS) on the subjects’ whole blood extracted DNA, multigene panel analysis for identification of individuals with cancer gene variants is performed.

Achievement: Determination of cancer risk in cases with familial cancer history.

ONCOASSAY® B

In Primary Cancer

Method: Using hybrid technology, which includes immunohistochemical and genomic tests, based on patient’s FFPE sample for more accurate characterization of tumors and the respective molecular pathways.

Achievement: Planning personalized treatment strategies, response prediction to immunotherapy, hormonal therapy, and targeted therapy as well as recurrence.

ONCOASSAY® C

In Metastatic Cancer

Method: Using FFPE sample (hybrid technology) using FFPE sample (hybrid technology) regarding both primary and metastatic tumor for characterization of specific molecular pathways of metastatic tumors, characterization of tumor dynamics, and tumor formation compared to primary tumor leading to precision molecular characterization of tumors.

Achievement: Planning personalized treatment strategies, response prediction to chemotherapy, immunotherapy, hormonal therapy, and targeted therapy as well as monitoring treatment effectiveness.

ONCOASSAY® M

In Treatment and Post-Treatment Phase

Method: Using liquid biopsy samples, Circulating Tumor Cells (CTCs) and/or Circulating Cell-Free-DNA (CCFD) for molecular and cellular characteristics of tumor cells and investigation of tumor progression.

Achievement: Tracking of CTCs, monitoring treatment effectiveness, planning personalized treatment strategies, response prediction to chemotherapy, immunotherapy, hormonal therapy, and targeted therapy.

ONCOTHERA

CANCER IMMUNOTHERAPY

ONCOTHERA is a personalized approach of cancer immunotherapy, specifically synthetized from patient’s tumor peptides.

A new generation of cancer vaccines has been developed for situations where viable tumor tissue is not available for a whole tumor vaccine. This peptide vaccine aims to identify only the immunogenic tumor antigens specific to each tumor. This new vaccine chooses only antigens commonly or expressed by the indication or expressed by the tumor, to create strong targeted and specific tumor vaccines.

There are two levels: the first is called The Universal Peptide. It is designed to target general mutations shared across various common indications and to work across a broad range of HLA blood types. It is available right away and works on most patients.

The second level is The Personalized Peptide. It requires a blood test to determine the HLA typing (Class I – low resolution 2-digit test). It also requires access to your paraffin block or slides to perform a genetic profiling test. Genetic profiling can also be ordered by your oncologist, or coordinated by us.

If previously conducted, the same results can be used. The vaccine is personalized to your blood type and to the identified mutations that are unique to your tumor.

ONCOTHERA I

Peptide or RNA Based Personalized Immunotherapy & Vaccination

ONCOTHERA II

Dc and/or Virus Based Personalized Immunotherapy

HEALI

HEALI is a personalized management program that considers all aspects of patient’s conditions through regular consultation meetings. In this service, there will be a team of doctors and geneticists by the patient’s side in order to define the cancer risk and best treatment strategies.

LIFE UP

LIFEUP is the ultimate VIP personalized management program in Germany. Our comprehensive service covers everything from A to Z, including the visa process, accommodation, diagnosis, and treatment of patients. Experience unparalleled care and convenience with LIFEUP, ensuring your health journey is seamless and stress-free.